BioSpace News Archive

Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, was named as winner in the Telehealth Innovation category at the University of California San Francisco (UCSF) Health Hub Digital Health Awards, at the 2022 HLTH conference.

ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) a leading US-based franchise system providing drug testing, alcohol screening, DNA and clinical lab testing services announced today that it expects to release financial results for the third quarter of 2022 before the market open Monday, November 28, 2022.

Aurora Spine Corporation today announced it will issue its financial results press release for the third quarter ended September 30, 2022, on Monday, November 21, 2022.

Simcere Pharmaceutical Group Ltd (2096.HK, “Simcere”) and Idorsia Ltd (SIX: IDIA, “Idorsia”), specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options, announced today that they have entered into an exclusive licensing agreement for Idorsia’s daridorexant in China.

Natera, Inc., a global leader in cell-free DNA testing, announced the pricing of its underwritten public offering of 11,430,000 shares of its common stock at a price to the public of $35.00 per share.

Natera, Inc. (Nasdaq: NTRA) (“Natera”), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $350,000,000 of shares of its common stock.

Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine months ended September 30, 2022.

Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of ASC10 for monkeypox indication.

YS Biopharma Co., Ltd. (“YS Biopharma” or the “Company”) today announced that its manufacturing facility for PIKA recombinant COVID-19 vaccine successfully passed an audit by a European Union (“EU”) Qualified Person (“QP”) and received QP declaration of its GMP equivalence to European Union Good Manufacturing Practice (“EU GMP”).

CANbridge Pharmaceuticals, Inc. (1228.HK) announced that CAN106, a clinical-stage recombinant humanized monoclonal antibody targeting C5, has been granted Orphan Drug Designation by the United States Food and Drug administration (FDA) for the treatment of myasthenia gravis (MG), an autoimmune neuromuscular disease that causes weakness in skeletal muscles.